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ABSTRACT
Aldosterone induces relevant effects binding to the mineralcorticoid receptor 
(MR), which acts as a ligand-gated transcription factor. Alternate mechanisms 
can mediate the action of aldosterone such as the activation of epidermal growth 
factor receptor (EGFR), MAPK/ERK, transcription factors and ion channels. The 
G-protein estrogen receptor (GPER) has been involved in the stimulatory effects 
of estrogenic signalling in breast cancer. GPER has been also shown to contribute 
to certain responses to aldosterone, however the role played by GPER and the 
molecular mechanisms implicated remain to be fully understood. Here, we evaluated 
the involvement of GPER in the stimulatory action exerted by aldosterone in breast 
cancer cells and breast tumor derived endothelial cells (B-TEC). Competition assays, 
gene expression and silencing studies, immunoblotting and immunofluorescence 
experiments, cell proliferation and migration were performed in order to provide 
novel insights into the role of GPER in the aldosterone-activated signalling. Our results 
demonstrate that aldosterone triggers the EGFR/ERK transduction pathway in a MR- 
and GPER-dependent manner. Aldosterone does not bind to GPER, it however induces 
the direct interaction between MR and GPER as well as between GPER and EGFR. Next, 
we ascertain that the up-regulation of the Na+/H+ exchanger-1 (NHE-1) induced by 
aldosterone involves MR and GPER. Biologically, both MR and GPER contribute to the 
proliferation and migration of breast and endothelial cancer cells mediated by NHE-1 
upon aldosterone exposure. Our data further extend the current knowledge on the 
molecular mechanisms through which GPER may contribute to the stimulatory action 
elicited by aldosterone in breast cancer.
INTRODUCTION
Aldosterone elicits multiple biological effects 
binding to the mineralcorticoid receptor (MR), which acts 
as a ligand-gated transcription factor [1]. In addition, rapid 
aldosterone signalling involves alternate mechanisms 
that include the activation of transduction pathways like 
tyrosine kinase c-Src, epidermal growth factor receptor 
(EGFR) and MAPK/ERK cascade [2-4]. Aldosterone is 
a key component of the renin-angiotensin-aldosterone 
system (RAAS), which is mainly implicated in maintaining 
salt and water balance toward the regulation of systemic 
blood pressure [5]. In addition, aldosterone activates ionic 
membrane transporters as the Na+/H+ exchanger (NHE-
1) and Na+/HCO3
- cotransporter (NBC), which regulate 
the cellular pH and volume [6-7]. Aldosterone has been 
also involved in diverse cardio-metabolic diseases as 
it triggers inflammatory and fibrotic responses in both 
heart and vessels [8-11]. Recent studies have suggested 
that aldosterone/MR signalling may contribute to the 
progression of certain types of tumor [12-13]. For 
instance, it has been shown that aldosterone stimulates 
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the survival and proliferation of renal carcinoma cells by 
upregulating K-RAS and the activation of the Akt and Raf 
pathways [12]. Moreover, an aldosterone blocker inhibited 
the growth of hepatocellular carcinoma and angiogenesis 
both in vitro and in vivo [13]. 
The G-protein estrogen receptor namely GPER 
mediates several pathophysiological functions in the 
cardiovascular, immune and central nervous systems, 
glucose and fat metabolism [14]. In addition, our and 
other previous studies have largely demonstrated that 
estrogenic GPER signalling elicits stimulatory effects in 
cancer cells and tumor microenvironment toward cancer 
progression [14-19]. In this regard, it has been reported 
that GPER activation triggers diverse transduction 
pathways involved in the proliferation, invasion and 
migration of tumor cells, including the epidermal growth 
factor receptor (EGFR), the MAPK/ERK and PI3K/
AKT transduction cascades, Ca2+ mobilization and cAMP 
production [20-27]. Numerous endogenous, environmental 
and newly synthesized molecules have been shown to 
trigger relevant GPER-mediated responses in different cell 
contexts [28-36]. Aldosterone has been recently suggested 
to act through GPER in diverse models, including the 
cardiovascular and renal systems [6, 37-40]. For instance, 
it was demonstrated that GPER is involved in important 
effects exerted by aldosterone on vascular endothelial 
cells, cardiac vagal tone and connecting tubule glomerular 
feedback [37-40]. These observations have pointed out 
the potential of GPER to contribute to the aldosterone 
action, however the effective role played by GPER and 
the molecular mechanisms implicated are controversial 
as pharmacologic criteria for considering GPER as an 
aldosterone receptor have been not adequately fulfilled 
[41-43]. 
In the framework of the aforementioned 
observations, the current study provides novel insights into 
the role of GPER in mediating the action of aldosterone 
in breast tumor. In particular, our data show that a 
functional cross-talk between MR and GPER may occur 
upon aldosterone treatment leading to stimulatory effects 
in both breast cancer cells and endothelial cells obtained 
from breast malignancies.
RESULTS
Aldosterone activates the EGFR/ERK 
transduction pathway and induces the interaction 
between MR and GPER
We began our study evaluating whether aldosterone 
could be able to activate the EGFR/ERK transduction 
signalling in SkBr3 breast cancer cells and B-TEC breast 
tumor-derived endothelial cells, which were used as model 
systems. Both cell types express MR and GPER but not 
ERα (Supplementary Figure 1). Of note, pM aldosterone 
concentrations induced the phosphorylation of EGFR and 
ERK1/2 in both SkBr3 cells and B-TEC (Figure 1A-1D), 
though these effects were no longer evident silencing the 
expression of MR (Figure 1E-1J). Recently, it has been 
reported that GPER contributes to aldosterone action 
although the mechanisms involved remain to be fully 
understood [6, 38-44]. In this vein, we therefore performed 
saturation curves and scatchard plot analyses using as 
radiotracers the GPER ligand [3H]E2 [28, 31-32, 34-36] 
and the MR ligand [3H]aldosterone. [3H]E2 showed an 
estimated Bmax corresponding to 6799 ± 707.8 cpm/1 × 
105 SkBr3 cells and an estimated Kd corresponding to 8.16 
± 1.70 nM (Figure 2A), whereas [3H]aldosterone showed 
an estimated Bmax corresponding to 2159 ± 229.2 cpm/1 
× 105 SkBr3 cells and an estimated Kd corresponding to 
0.42 ± 0.08 nM (Figure 2B). In competition assays, E2 
but not aldosterone displaced [3H]E2 (Figure 2C), while 
aldosterone but not E2 displaced [3H]Aldosterone (Figure 
2D). Collectively, these findings argue that in SkBr3 cells 
aldosterone is not able to displace [3H]E2, which was used 
as a GPER radioligand.
In order to gain further insights into the role of 
GPER in certain biological responses to aldosterone, we 
then evaluated the possible interaction of GPER and MR 
and EGFR. Our immunoprecipitation data indicated that 
aldosterone triggers a direct interaction between GPER 
and MR as well as GPER and EGFR (Figure 2E-2L). 
Immunofluorescence experiments performed in SkBr3 
cells further corroborated the aforementioned results as 
an increased merged (orange) signal of MR and GPER 
was observed upon a short (15 min) aldosterone treatment 
(Figure 2M-2O). Altogether, these data suggest that 
GPER may contribute to aldosterone/MR-activated EGFR 
signalling.
GPER is involved in the aldosterone-mediated 
signalling
On the basis of the abovementioned observations, 
we performed gene silencing experiments in order to 
assess whether GPER is involved in the rapid signalling 
induced by aldosterone. Interestingly, the activation of 
both EGFR and ERK1/2 by aldosterone was no longer 
evident silencing GPER in both SkBr3 cells and B-TEC 
(Figure 3A-3F). In accordance with these findings, 
the GPER antagonist G15 prevented the EGFR/ERK 
phosphorylation upon aldosterone exposure (Figure 3G-
3I). Next, the EGFR tyrosine kinase inhibitor AG1478 
(AG) but not the MEK inhibitor PD98059 (PD) blocked 
EGFR phosphorylation by aldosterone (Figure 3G-3I), 
while ERK1/2 activation was prevented in the presence 
of both AG and PD. Hence, the MEK/ERK transduction 
pathway is activated afterward the engagement of 
EGFR upon aldosterone treatment in our model system. 
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Figure 1: EGFR and ERK1/2 phosphorylation in SkBr3 cells. A., B. and B-TEC C., D. treated with Aldosterone (Aldo) for 15 
min. EGFR and ERK1/2 phosphorylation in SkBr3 cells E., F. and B-TEC H., I. transfected for 24 h with siRNA or siMR and then treated 
with 10 pM Aldo for 15 min. G., J. Efficacy of MR silencing. The blots were normalized to EGFR or ERK2 and each data point represents 
the mean ± SD of three independent experiments. (○) and (●) indicate p < 0.05 for cells receiving vehicle (-) versus Aldo treatment.
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Figure 2: Representative saturation curve and Scatchard plot of [3H]17β-estradiol (E2) binding. A. and [3H]Aldosterone 
(Aldo) binding B. in SkBr3 cells. Each value represents the mean ± SEM of three determinations. Ligand binding assay in SkBr3 cells 
incubated with [3H]E2 and exposed to increasing concentrations of E2 and Aldo for 2 hours C.. Ligand binding assay in SkBr3 cells 
incubated with [3H]Aldo and exposed to increasing concentrations of E2 and Aldo for 2 hours D.. Competition curves are expressed as a 
percentage of maximum specific [3H]E2 or [3H]Aldo binding. Each data point represents the mean ± SEM of three independent experiments 
performed in triplicate. The co-immunoprecipitation of MR with GPER increases upon treatment with 10 pM Aldo for 15 min in SkBr3 
cells E.-H. The blots were normalized to GPER or MR, respectively. The interaction between GPER and EGFR increases upon treatment 
with 10 pM Aldo for 15 min in SkBr3 cells I.-L. The blots were normalized to GPER or EGFR, respectively. In control samples, nonspecific 
IgG was used instead of the primary antibody, as indicated. Each data point represents the mean ± SD of three independent experiments. 
(○) indicates p < 0.05 for cells receiving vehicle (-) versus Aldo treatment. Localization of MR M. and GPER N. alone or in combination 
O., as evaluated by immunofluorescence in SkBr3 cells treated with 10 pM Aldo for 15 min. Green signal: MR; Red signal: GPER; Blue 
signal: Nuclei. Images shown are representative of ten random fields from three independent experiments.
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Figure 3: EGFR and ERK1/2 phosphorylation in SkBr3 cells. A., B. and B-TEC D., E. transfected for 24 h with shRNA or 
shGPER and then treated with 10 pM Aldo for 15 min. C., F. Efficacy of GPER silencing. EGFR and ERK1/2 activation in SkBr3 cells G., 
H. and B-TEC I., J. treated for 15 min with 10 pM Aldo alone and in combination with 10 µM EGFR inhibitor AG1478 (AG), 10 µM MEK 
inhibitor PD98059 (PD) and 100 nM GPER antagonist G15. The blots were normalized to EGFR or ERK2 and each data point represents 
the mean ± SD of three independent experiments. (○) and (●) indicate p < 0.05 for cells receiving vehicle (-) versus Aldo treatment.
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Aldosterone/MR signalling stimulates the activity and 
expression of NHE-1, which has been involved in tumor 
cell migration, invasion and metastasis particularly in 
breast cancer [6-7, 45]. In this regard, we assessed that 
aldosterone prompts NHE-1 activity in both SkBr3 
cells and B-TEC as evaluated by a fluorescent indicator 
of cytoplasmic pH changes (Figure 4A). In addition, 
aldosterone up-regulated NHE-1 at both the mRNA and 
protein levels as determined by real time PCR (Figure 4B) 
and immunofluorescence studies performed in SkBr3 cells 
and B-TEC (Figure 4C-4F). Next, the stimulatory effects 
induced by aldosterone on NHE-1 protein expression 
were abolished silencing MR (Figure 5) as well as GPER 
(Figure 6). Collectively, these findings suggest that NHE-1 
regulation by aldosterone requires MR along with GPER.
Aldosterone induces biological responses through 
both MR and GPER
Functionally, we studied the role of MR and GPER 
in the proliferative effects of aldosterone in breast tumor 
cells as well as in the migration of tumor endothelial 
cells. Indeed, aldosterone triggered growth effects in 
SkBr3 cells, as assessed by cell counting (Figure 7A) and 
evidenced by time-lapse video microscopy (Videos 1-2). 
Cell proliferation stimulated by 10pM aldosterone was no 
longer evident silencing MR (Figure 7B-7C) or knocking-
down GPER expression (Figure 7D-7E) and using the 
NHE-1 inhibitor cariporide (Figure 7F). Similar results 
were obtained using aldosterone concentrations up to 10 
nM (data not shown). Furthermore, aldosterone promoted 
the migration of B-TEC as evidenced by time-lapse video 
microscopy (Videos 3-4) and scratch assay (Figure 8). 
The observed aldosterone-induced motility was abrogated 
silencing MR (Figure 8A, 8B, 8F) or GPER (Figure 
8C-8D, 8G) and in the presence of cariporide (Figure 
8E). Overall, these results indicate that the functional 
interaction between MR and GPER is involved in the 
aforementioned stimulatory action of aldosterone in both 
SkBr3 cells and B-TEC. 
DISCUSSION
In the present study we provide novel evidence 
regarding the molecular mechanisms by which GPER 
may contribute to the biological responses induced by 
aldosterone in breast cancer cells and breast tumor-derived 
endothelial cells. In particular, we have demonstrated 
that aldosterone activates the EGFR/ERK transduction 
signalling through the classic MR and the involvement 
of GPER, as evidenced by gene silencing experiments 
and pharmacological inhibitors. In addition, we have 
shown that both MR and GPER mediate the aldosterone-
induced up-regulation of Na+/H+ exchanger-1 (NHE-1), 
a well-known MR target involved in cancer progression 
[7, 45]. We have also evidenced that aldosterone does not 
bind to GPER in accordance with previous studies [44], 
however it triggers the direct interaction between MR 
and GPER as well as GPER and EGFR. Interestingly, we 
have determined that both MR and GPER are required for 
the proliferation and migration of breast cancer cells and 
B-TEC mediated by NHE-1 upon aldosterone exposure. 
Aldosterone elicits important biological effects 
in several physio-pathological conditions, spanning 
from electrolyte and fluid homeostasis to the regulation 
of fibrotic, inflammatory, proliferative and angiogenic 
responses in cardiovascular, metabolic diseases and 
cancer [12-13, 46-49]. As it concerns the breast tissue, 
it has been demonstrated that aldosterone potentiates 
prolactin stimulation of casein synthesis in pregnant 
rabbit mammary gland and contributes to mammary gland 
development and differentiation [50]. 
The actions exerted by aldosterone mainly 
occur through the binding to MR, a ligand-inducible 
transcription factor that belongs to the nuclear receptor 
superfamily [1]. The enzyme 11β-hydroxysteroid 
dehydrogenase type II (11βHSD2), which catalyzes the 
conversion of 11β-hydroxycorticosteroids like cortisol 
and corticosterone to the respective 11-keto metabolites 
namely cortisone and 11-dehydrocorticosterone, does 
allow the aldosterone binding to MR [51]. 11βHSD2 
is mainly expressed in mineralcorticoid target tissues 
like kidney, colon, salivary glands and placenta [51]. In 
addition, immunohistochemical studies have detected 
in normal and malignant breast tissues high levels of 
11β-HSD2 that co-localize with MR [52]. Previous 
studies have also evaluated the 11β-HSD2 activity in 
breast cancer cells, suggesting that this enzyme may 
play a regulatory role of aldosterone action in breast 
malignancy [53]. According to the classical model of 
MR signalling, the interaction between aldosterone and 
un-liganded receptor promotes the dissociation of the 
heat shock proteins from MR, which translocates into the 
nucleus [1]. Then, the aldosterone/MR complex binds to 
specific response elements located within the regulatory 
region of target genes, hence resulting in gene expression 
changes [1]. In addition, aldosterone induces rapid effects 
through alternate mechanisms including the activation of 
the EGFR/ERK transduction pathway, as demonstrated 
in different animal and cell models [3-4]. The existence 
of aldosterone receptors structurally unrelated to the 
classic MR paved also the way for analyzing the role of 
further mediators of the multifaceted action elicited by 
aldosterone [49]. 
GPER has been largely demonstrated to mediate 
estrogenic signalling in a wide number of physio-
pathological conditions, including cancer [54-64]. 
GPER has been also involved in functional responses 
to aldosterone in various experimental contexts [37-
40]. For instance, the ability of aldosterone in activating 
ERK1/2 in vascular smooth muscle cells and sensitizing 
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Figure 4: Na+/H+ Exchanger 1 (NHE-1) activity in SkBr3 cells and B-TEC treated with 10 pM Aldo, as evaluated 
by fluorescence intensity measurement. A. Each data point represents the mean ± SD of three independent experiments. mRNA 
expression of NHE-1 in SkBr3 cells and B-TEC treated with 10 pM Aldo, as evaluated by real-time PCR B.. Values are normalized to 
the 18S expression and shown as fold changes of the mRNA expression induced by Aldo respect to cells treated with vehicle (-). NHE-1 
expression as evaluated by immunofluorescence in SkBr3 cells C. and B-TEC E. treated with ethanol as vehicle or 10 pM Aldo for 8 hours. 
NHE-1 accumulation is shown by the red signal, nuclei were stained by DAPI (blue signal). Images shown are representative of three 
independent experiments. D., F. Fluorescence intensities for the red channel were quantified in 10 random fields for each condition and 
results are expressed as fold change of relative fluorescence units (RFU) over the vehicle-treated cells. (○) and (●) indicate p < 0.05 for cells 
receiving vehicle (-) versus Aldo treatment. 
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Figure 5: Na+/H+ Exchanger 1 (NHE-1) expression as evaluated by immunofluorescence in SkBr3 cells. A. and B-TEC D. 
transfected for 24 hours with siRNA (panels 1-6) or siMR (panels 7-12) and then treated with ethanol as vehicle or 10 pM Aldosterone (Aldo) 
for 8 hours. NHE-1 accumulation is shown by the red signal, nuclei were stained by DAPI (blue signal). Images shown are representative 
of three independent experiments. B., E. Fluorescence intensities for the red channel were quantified in 10 random fields for each condition 
and results are expressed as fold change of relative fluorescence units (RFU) over the vehicle-treated cells. C., F. Efficacy of MR silencing. 
(○) indicates p < 0.05 for cells receiving vehicle versus Aldo treatment. 
Oncotarget102www.impactjournals.com/oncotarget
Figure 6: Na+/H+ Exchanger 1 (NHE-1) expression as evaluated by immunofluorescence in SkBr3 cells. A. and B-TEC D. 
transfected for 24 hours with shRNA (panels 1-6) or shGPER (panels 7-12) and then treated with ethanol as vehicle or 10 pM aldosterone 
(Aldo) for 8 hours. NHE-1 accumulation is shown by the red signal, nuclei were stained by DAPI (blue signal). Images shown are 
representative of three independent experiments. B., E. Fluorescence intensities for the red channel were quantified in 10 random fields for 
each condition and results are expressed as fold change of relative fluorescence units (RFU) over the vehicle-treated cells. C., F. Efficacy 
of GPER silencing. (○) indicates p < 0.05 for cells receiving vehicle (-) versus Aldo treatment. 
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the connecting tubule glomerular feedback in afferent 
arterioles was prevented using both MR and GPER 
blockers [38-40]. Other studies evidenced that the increase 
of cardiac vagal tone observed upon aldosterone treatment 
is abolished in the presence of the GPER antagonist G36 
but not using the MR antagonists spironolactone and 
eplerenone [39]. In rat aortic endothelial cells devoid 
of MR, the biological effects triggered by aldosterone 
were mimicked by the GPER agonist G-1 and prevented 
using pharmacological inhibitors of GPER as well as 
knocking down its expression [38]. The aforementioned 
observations suggest that GPER is involved in the effects 
exerted by aldosterone either through MR or acting as 
an alternate aldosterone receptor. However, it should be 
pointed out that diverse controversies argue against the 
last conclusion, as pharmacologic criteria for GPER to be 
considered as an aldosterone-responsive receptor are not 
still adequately fulfilled [41-43]. Indeed, binding studies 
performed in HEK cells overexpressing GPER (HEK-
GPER-1) showed that aldosterone and the MR antagonists, 
spironolactone and eplerenone, do not compete for specific 
[3H]E2 binding to membrane of HEK-GPER-1 cells [44]. 
Figure 7: A. SkBr3 cell proliferation upon treatment for 5 days with increasing concentrations of Aldosterone (Aldo). Proliferation of 
SkBr3 cells transfected with siMR B., C. and shGPER D., E. and treated for 5 days with 10 pM Aldo. SkBr3 cell proliferation stimulated 
by 10 pM Aldo in the presence of 50 µM Na+/H+ Exchanger 1 (NHE-1) inhibitor named cariporide F.. Values shown are mean ± SD of three 
independent experiments performed in triplicate. (○) indicates p < 0.05 for cells receiving vehicle (-) versus Aldo treatment. 
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In accordance with these findings, in the present study 
aldosterone failed to bind to GPER in competition assays 
based on experimental approaches used in previous 
investigations in order to characterize the binding 
properties of GPER ligands [28, 31-32, 34-36]. Worthy, we 
found that aldosterone stimulates the interaction of GPER 
with MR and EGFR, thus suggesting a further mechanism 
through which ligand-activated MR triggers EGFR 
signalling [49, 65-67]. Nicely supporting the functional 
cross-talk between MR and GPER, we ascertained that 
both receptors are required for the aldosterone-induced 
expression of NHE-1 which is considered as a molecular 
sensor of MR activation [45]. In this respect, our data are 
reminiscing of previous findings showing that EGFR and 
GPER cooperate toward the regulation of NHE-1 function 
upon aldosterone treatment [40, 66]. Importantly, we 
found that the stimulatory effects elicited by aldosterone 
on the proliferation and migration of breast cancer cells 
and breast tumor-derived endothelial cells are mediated 
by NHE-1 and involve both GPER and MR. Hence, the 
current results further extend the well-known action 
played by NHE-1 toward negative biological features, in 
particular in breast cancer [7, 68]. In this regard, it is worth 
mentioning that in tumor metabolic microenvironment 
Figure 8: Cell migration in B-TEC transfected for 24 h with siRNA. A., siMR B., shRNA C. or shGPER D. and then treated 
for 48 hours with ethanol as vehicle or 10 pM Aldosterone (Aldo). E. Cell migration stimulated by 10 pM Aldo in B-TEC in the presence 
of 50 µM Na+/H+ Exchanger 1 (NHE-1) inhibitor cariporide. F., G. Efficacy of MR and GPER silencing. Data are representative of three 
independent experiments performed in triplicate.
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characterized by hypoxic-acidic milieu [69], the 
dysregulation of pH homeostasis mediated by NHE-1 
may actually contribute to key steps in tumor progression 
like increased cell proliferation, loss of cell-cell contact 
and detachment from the extracellular matrix [68]. In 
breast cancer cells and breast cancer associated fibroblasts 
exposed to hypoxia, we have previously assessed that 
GPER cooperates with hypoxia inducible factor-1 (HIF-
1) toward the regulation of vascular endothelial growth 
factor (VEGF) and tumor angiogenesis [70-73]. Hence, 
the present findings suggest further mechanisms through 
which GPER may play a role in the complex adaptive 
responses to hypoxic-acidic tumor microenvironment. 
Additionally, our results indicate that GPER contributes 
to the effects mediated by aldosterone/MR signalling, as 
evidenced by other ligand-activated steroid receptors [74-
75]. 
Collectively, our findings provide novel insights 
into the controversial mechanisms through which GPER 
contributes to aldosterone-mediated signalling. On the 
basis of our data showing that the functional interaction 
between MR and GPER triggers certain stimulatory 
effects exerted by aldosterone, GPER may be considered 
as a further target within the intricate transduction network 
activated by aldosterone in particular in breast cancer.
MATERIALS AND METHODS
Reagents
Aldosterone (Aldo), 17β-estradiol (E2) and 
Cariporide were purchased from Sigma Aldrich (Milan, 
Italy). G15 ((3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-
5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinolone) was 
obtained from Tocris Bioscience (distributed by Space, 
Milan, Italy). Tyrphostin AG1478 (AG) was purchased 
from DBA (Milan, Itay). PD98059 (PD) was obtained 
from Calbiochem (DBA, Milan, Italy). All compounds 
were dissolved in dimethyl sulfoxide (DMSO) except 
Aldosterone and E2 which were solubilized in ethanol.
Cell cultures
SkBr3 breast cancer cells were maintained in 
RPMI-1640 without phenol red, supplemented with 
10% fetal bovine serum (FBS) and 100 μg/ml penicillin/
streptomycin (Life Technologies, Milan, Italy). Breast 
tumor-derived endothelial cells (B-TEC) were obtained 
from human breast carcinomas and characterized as 
previously described [76]. B-TEC showed constant 
expression of endothelial markers and increased 
angiogenic properties, migration and drug resistance 
in respect to normal microendothelial cells [76-78]. 
Briefly, specimens were finely minced with scissors and 
then digested by incubation for 1 h at 37˚C in DMEM 
containing collagenase IV (Sigma Aldrich, Milan, 
Italy). After washings in medium plus 10% FCS (Life 
Technologies, Milan, Italy), the cell suspension was 
forced through a graded series of meshes to separate the 
cell components from stroma and aggregates. Endothelial 
cells were isolated from cells suspension using anti-
CD105 Ab coupled to magnetic beads, by magnetic 
cell-sorting using the MACS system (Miltenyi Biotech, 
Auburn, CA). B-TEC were seeded on collagen-coated 
flasks (Sigma-Aldrich Srl, Milan, Italy) and cultured in 
Endothelial Growth Medium (EGM) (Lonza, Milan, 
Italy), supplemented with 5% FBS (Lonza, Milan, Italy). 
MCF-7 breast cancer cells were maintained in DMEM 
F12 supplemented with 10% FBS and 100 µg/mL 
penicillin/streptomycin (Life Technologies, Milan, Italy). 
All cell lines were grown in a 37° C HeraCell incubator 
(ThermoScientific-Heraeus, Milan, Italy) with 5% CO2. 
Cells were switched to medium without serum the day 
before experiments.
Saturation curve and scatchard plot analysis
SkBr3 cells were grown in 10-cm cell culture dishes 
and incubated with increasing concentrations of [2, 4, 6, 
7-3H] E2 (89 Ci/mmol; GE Healthcare) or [1, 2, 6, 7-3H] 
Aldosterone (85 Ci/mmol; Perkinelmer). Cells were then 
washed with ice-cold phosphate-buffered saline (PBS); 
after 100% ethanol extraction of cells, radioactivity was 
measured by liquid scintillation counting. The plot of the 
bound radioactivity (cpm) versus the concentration of the 
radiotracer (nM) was fitted to the saturation binding curve 
using Prism GraphPad program (GraphPad Software, 
San Diego, CA), which was used to calculate the binding 
dissociation constant (Kd) and binding capacity (Bmax). 
Ligand binding assay
SkBr3 cells were grown in 10-cm cell culture 
dishes and incubated with 4 nM [2, 4, 6, 7-3H] E2 (89 
Ci/mmol; GE Healthcare) or 100 pM [1, 2, 6, 7-3H] 
Aldosterone (85 Ci/mmol; Perkinelmer) in the presence 
or absence of increasing concentrations of nonlabeled 
E2 or aldosterone for 2 hours at 37°C. Cells were then 
washed with ice-cold PBS; after 100% ethanol extraction 
of cells, radioactivity was measured by liquid scintillation 
counting. The displacement of [3H]E2 or [3H]Aldo binding 
by the competitors was expressed as a percentage of the 
maximum specific binding of E2 or Aldo.
Na+/H+ Exchanger 1 (NHE-1) activity assay
 SkBr3 cells and B-TEC were grown in 10-cm 
cell culture dishes and then shifted for 24h to medium 
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lacking serum. Then, 4x107 cells/ml were suspended in 
HEPES buffer solution 1M (Sigma Aldrich, Milan, Italy) 
and incubated with a membrane-permeable fluorescent 
indicator for the measurement of cytoplasmic pH 
namely SPIRO(ISOBENZOFURAN-1(3H),9’-(9H)
XANTHENE)-2’,7’-DIPROPANOIC ACID (BCECF-
AM) (0,3μM) (Santa Cruz Biotechnology, Milan, Italy) 
for 30 min at 37°C. Then, cells were washed with HEPES 
buffer saline and a cell suspension of 3x106 cells/ml was 
prepared. Fluorescence ratio from the dye was measured 
using an FLX-800 micro plate fluorimeter (Bio-Tek 
Instruments, Inc., Winooski, VT, USA). 
Gene expression studies
Total RNA was extracted from cell cultures using 
the TRIzol commercial kit (Life Technologies, Milan, 
Italy) according to the manufacturer’s protocol. RNA 
was quantified spectrophotometrically and quality 
was checked by electrophoresis through agarose gels 
stained with ethidium bromide. Only samples that were 
not degraded and showed clear 18 S and 28 S bands 
under UV light were used for RT-PCR. Total cDNA 
was synthesized from the RNA by reverse transcription 
using the murine leukemia virus reverse transcriptase 
(Life Technologies, Milan, Italy), following the protocol 
provided by the manufacturer. The expression of selected 
genes was quantified by real-time PCR using Step One 
(TM) sequence detection system (Applied Biosystems 
Inc, Milan, Italy), following the manufacturer’s 
instructions. Gene-specific primers were designed 
using Primer Express version 2.0 software (Applied 
Biosystems. Inc., Milan, Italy) and are as follows: 
GPER Fwd: 5’-ACACACCTGGGTGGACACAA-3’ 
and Rev: 5’-GGAGCCAGAAGCCACATCTG-3’; 
MR Fwd: 5’-GCTTTGATGGTAACTGTGAAGG-3’ 
and Rev: 5’- TGTGTTGCCCTTCCACTGCT-3’; ERα 
Fwd: 5’-AGAGGGCATGGTGGAGATCTT-3’ and 
Rev: 5’-CAAACTCCTCTCCCTGCAGATT-3’; NHE-
1 Fwd: 5’:- AAGGACCAGTTCATCATCGC-3’ and 
Rev:5’- TTCTTCACAGCCAACAGGTC-3’; 18S 
Fwd: 5’-GGCGTCCCCCAACTTCTTA-3 and Rev: 
5’-GGGCATCACAGACCTGTTATT-3’. Assays were 
performed in triplicate and the RNA expression values 
were normalized using 18S expression and then calculated 
as fold induction.
Gene silencing experiments
For the silencing of GPER expression, cells were 
plated onto 10-cm dishes and transfected using X-treme 
GENE 9 DNA Transfection Reagent (Roche Diagnostics, 
Milan, Italy) for 24 hours with two shRNA and two 
different shGPER. The silencing of GPER expression 
was obtained by using constructs which we have 
previously described and used [79]. For knocking down 
MR expression, cells were seeded in six-well multidishes 
and transiently transfected the consecutive day at 50% 
confluence. For transfection, X-treme GENE 9 DNA 
Transfection Reagent (Roche Diagnostics, Milan, Italy) 
was mixed with two small interfering RNAs (siRNA) 
specific for silencing MR or two siRNA controls (Origene, 
distributed by Tema Ricerca, Milan, Italy) for 24 hours, 
prior to treatments.
Western blot analysis
SkBr3 cells and B-TEC were processed according 
to a previously described protocol [80-81] to obtain 
protein lysate that was electrophoresed through a reducing 
SDS/10% (w/v) polyacrylamide gel, electroblotted onto 
a nitrocellulose membrane and probed with primary 
antibodies against MR (PA1594) (Boster Immunoleader, 
distributed by Tema Ricerca, Milan, Italy), phosphorylated 
ERK 1/2 (E-4), ERK2 (C-14), EGFR (1005), pEGFRTyr 
1173 (sc-12351-R), GPER (N15), ERα (F10) and β-actin 
(C2), all purchased from DBA (Milan, Italy). Proteins 
were detected by horseradish peroxidase-linked secondary 
antibodies (DBA, Milan, Italy) and revealed using the 
ECL System (GE Healthcare). Precision Plus Protein™ 
Dual Color Standard (Bio-Rad Laboratories, Milan, Italy) 
was used to estimate molecular weights and then antigen 
specificity. 
Coimmunoprecipitation
After stimulation with 10 pM Aldo, SkBr3 breast 
cancer cells were washed with PBS and lysed using 500 
µl RIPA buffer with a mixture of protease inhibitors 
containing 1.7 mg/ml aprotinin, 1mg/ml leupeptin, 200 
mmol/liter phenylmethylsulfonyl fluoride, 200 mmol/
liter sodium orthovanadate, and 100 mmol/liter sodium 
fluoride. Samples were then centrifuged at 13,000 rpm for 
10 min, and protein concentrations were determined using 
Bradford reagent. Protein (250 µg) was then incubated for 
2 hours with 900 µl of immunoprecipitation buffer with 
inhibitors, 2 µg of GPER, MR or EGFR antibody and 20 
µl of Protein A/G agarose immunoprecipitation reagent 
(DBA, Milan, Italy). Samples were then centrifuged at 
13,000 rpm for 5 min at 4° C to pellet beads. Pellets were 
washed four times with 500 µl of PBS and centrifuged at 
13,000 rpm for 5 min at 4° C. Supernatants were collected, 
resuspended in 20 µl RIPA buffer with protease inhibitors, 
2X SDS sample buffer (40 mM Tris-HCl; 4% glycerol; 
2% SDS) and β-mercaptoethanol and heated to 95° C 
for 5 min. Samples were then run on 10% SDS-PAGE, 
transferred to nitrocellulose, and probed with rabbit anti-
GPER, rabbit anti-MR or rabbit anti-EGFR antibody. 
Western blot analysis and ECL detection were performed 
as described above. 
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Immunofluorescence and colocalization studies
50 % confluent cultured SkBr3 cells and B-TEC 
grown on coverslips were serum deprived and then treated 
for 8 hours with 10 pM Aldo, as indicated. Where required, 
cells previously transfected for 24 hours with shGPER or 
siMR and respective control (as described above) and 
then treated for 8 hours with 10 pM Aldo. Then cells were 
fixed in 4% paraformaldehyde, permeabilized with 0.2% 
Triton X-100, washed three times with PBS and incubated 
overnight with a goat primary antibody against NHE-1 
(C20) (DBA, Milan, Italy). After incubation, the slides 
were extensively washed with PBS and incubated with 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), 
(1:1000), (Sigma-Aldrich, Milan, Italy) and donkey 
anti-goat IgG-Rhodamine (1:100; purchased from DBA, 
Milan, Italy). The slides were imaged on the Cytation 3 
Cell Imaging Multimode reader (BioTek, Winooski, VT) 
and analysed using the software Gen5 (BioTek, Winooski, 
VT). 
For colocalization studies SkBr3 cells seeded on 
chamber slides were serum deprived for 24 hours and 
then treated for 15 min with 10 pM Aldo. Next, cells were 
fixed, permeabilized and incubated overnight with anti-
rabbit GPER (N15) and anti-mouse MR (H10E4C9F) 
antibodies (DBA, Milan, Italy) alone and in combination. 
Slides were then incubated with secondary antibodies 
(donkey anti-rabbit IgG-Rhodamine, DBA, Milan, Italy) 
and donkey anti-mouse IgG-Fitch (Alexa Fluor, Life 
Technologies, Milan, Italy), stained by DAPI and then 
imaged on the Cytation 3 Cell Imaging Multimode reader 
(BioTek, Winooski, VT).
Proliferation assay
For quantitative proliferation assay, SkBr3 cells (1 
× 105) were seeded in 24-well plates in regular growth 
medium. Cells were washed once they had attached and 
then incubated in medium containing 2.5% charcoal-
stripped FBS, transfected for 24 hours, and then treated, 
as indicated, with transfection and treatments renewed 
every 2 days. Cells were counted on day 5 using the 
Countess Automated Cell Counter, as recommended by 
the manufacturer’s protocol (Life Technologies, Milan, 
Italy).
Migration assay
Twelve-well plates were coated with 500 μL 
fibronectin for 2 hours at 37°C (Sigma Aldrich, Milan, 
Italy). B-TEC were allowed to grow in regular growth 
medium until they reached a 70% to 80% confluence. 
Next, cells were incubated in medium containing 2.5% 
charcoal-stripped FBS and transfected for 24 hours, as 
indicated. To create a scratch of the cell monolayer, a p200 
pipette tip was used. Cells were then washed twice with 
PBS and treated. The migration assay was evaluated after 
48 hours of treatment.
Time-lapse microscopy
SkBr3 cells and B-TEC (1 × 105) were seeded 
in 24-well plates in regular growth medium until they 
reached a 70% to 80% confluence. The culture wells were 
then incubated in medium containing 2.5% charcoal-
stripped FBS, treated and transferred into a time-lapse 
microscopy platform, equipped with a heated stage 
chamber (Cytation™3 Cell Imaging Multi-Mode Reader, 
Biotek, Winooski, VT). Cells were maintained at routine 
incubation settings (37 °C, 5% CO2) using temperature 
and gas controllers. To evaluate cell proliferation and 
motility, the images were recorded using Cytation 3 
Cell Imaging Multimode Reader and the software Gen5 
(BioTek, Winooski, VT) in 10 min intervals for 24 hours 
(cell proliferation) and 10 hours (cell motility). Then, the 
images were processed as a movie using the software 
Adobe Creative Cloud Premier Pro CC. Frames collected 
every 10 minutes are displayed at a rate of 10 frames s-1. 
Statistical analysis
Statistical analysis was performed using ANOVA 
followed by Newman-Keuls’ testing to determine 
differences in means. p < 0.05 was considered as 
statistically significant.
ACKNOWLEDGMENTS
We thank A. Brossa and N. Fico for the technical 
support. 
COMPETING INTERESTS
The authors declare that they have no competing 
interests.
GRANT SUPPORT
This work was supported by Associazione Italiana 
per la Ricerca sul Cancro (AIRC grant 16719/2015), 
Programma Operativo Nazionale  “RIicerca e 
Competitività 2007-2013” (PON 01_01078), Ministero 
della Salute (grant n. 67/GR-2010-2319511). EMDF was 




1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin 
BL, Housman DE, Evans RM. Cloning of human 
mineralocorticoid receptor complementary DNA: structural 
and functional kinship with the glucocorticoid receptor. 
Science. 1987; 237: 268-275.
2. Meinel S, Gekle M, Grossmann C. Mineralocorticoid 
receptor signaling: crosstalk with membrane receptors and 
other modulators. Steroids. 2014; 91: 3-10. 
3. Williams JS. Evolving research in nongenomic actions of 
aldosterone. Curr Opin Endocrinol Diabetes Obes. 2013; 
20: 198-203. 
4. Krug AW, Grossmann C, Schuster C, Freudinger R, 
Mildenberger S, Govindan MV, Gekle M. Aldosterone 
stimulates epidermal growth factor receptor expression. J 
Biol Chem. 2003; 278: 43060-43066.
5. Paul M, Poyan Mehr A, Kreutz R. Physiology of local 
renin-angiotensin systems. Physiol Rev. 2006; 86: 747-803.
6. De Giusti VC, Orlowski A, Ciancio MC, Espejo MS, 
Gonano LA, Caldiz CI, Vila Petroff MG, Villa-Abrille 
MC, Aiello EA. Aldosterone stimulates the cardiac sodium/
bicarbonate cotransporter via activation of the g protein-
coupled receptor gpr30. J Mol Cell Cardiol. 2015; [Epub 
ahead of print] PMID: 26497404.
7. Amith SR, Fliegel L. Regulation of the Na+/H+ Exchanger 
(NHE-1) in Breast Cancer Metastasis. Cancer Res. 2013; 
73: 1259-1264.
8. Luther JM, Brown NJ. The renin-angiotensin-aldosterone 
system and glucose homeostasis. Trends Phamacol Sci. 
2011; 32: 734-739.
9. Briet M, Schiffrin EL. Vascular actions of aldosterone. J 
Vasc Res. 2013; 50: 89-99.
10. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-
Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad 
F, Rossignol P, López-Andrés N. Galectin-3 mediates 
aldosterone-induced vascular fibrosis. Arterioscler Thromn 
Vasc Biol. 2013; 33: 67-75.
11. Bienvenu LA1, Morgan J, Rickard AJ, Tesch GH, Cranston 
GA, Fletcher EK, Delbridge LM, Young MJ. Macrophage 
mineralocorticoid receptor signaling plays a key role in 
aldosterone-independent cardiac fibrosis. Endocrinology. 
2012; 153: 3416-3425.
12. King S, Bray S, Galbraith S, Christie L, Fleming S. 
Evidence for aldosterone-dependent growth of renal cell 
carcinoma. Int J Exp Pathol. 2014; 95: 244-250. 
13. Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, 
Shirai Y, Yoshii J, Yanase K, Namisaki T, Yamazaki M, 
Tsujimoto T, Kawaratani H, Fukui H. Selective aldosterone 
blocker, eplerenone, attenuates hepatocellular carcinoma 
growth and angiogenesis in mice. Hepatol Res. 2010; 40: 
540-549. 
14. Maggiolini M, Picard D. The unfolding stories of GPR30, 
a new membrane-bound estrogen receptor. J Endocrinol. 
2010; 204: 105-114.
15. Prossnitz ER, Barton M. The G-protein-coupled estrogen 
receptor GPER in health and disease. Nat Rev Endocrinol. 
2011; 7: 715-726.
16. Barton M. Position paper: The membrane estrogen receptor 
GPER—Clues and questions. Steroids. 2012; 77: 935-942. 
17. Filardo EJ, Thomas P. Minireview: G protein-coupled 
estrogen receptor-1, GPER-1: its mechanism of action 
and role in female reproductive cancer, renal and vascular 
physiology. Endocrinology. 2012; 153: 2953-2962. 
18. Meyer MR, Prossnitz ER, Barton M. The G protein-
coupled estrogen receptor GPER/GPR30 as a regulator of 
cardiovascular function. Vascul Pharmacol. 2011; 55: 17-
25. 
19. Lindsey SH, Chappell MC. Evidence that the G protein-
coupled membrane receptor GPR30 contributes to the 
cardiovascular actions of estrogen. Gend Med. 2011; 8: 
343-354. 
20. Prossnitz ER, Maggiolini M. Mechanisms of estrogen 
signaling and gene expression via GPR30. Molecular and 
Cellular Endocrinology. 2009; 308: 32-38.
21. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. 
Estrogen-induced activation of Erk-1 and Erk-2 requires the 
G protein-coupled receptor homolog, GPR30, and occurs 
via trans-activation of the epidermal growth factor receptor 
through release of HB-EGF. Mol Endocrinol. 2000; 14: 
1649-1660.
22. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, 
Prossnitz ER. A transmembrane intracellular estrogen 
receptor mediates rapid cell signaling. Science. 2005; 307: 
1625-1630. 
23. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini 
M, Picard D. Estrogenic GPR30 signalling induces 
proliferation and migration of breast cancer cells through 
CTGF. EMBO J. 2009; 28: 523-532.
24. Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua 
A, Sisci D, Abonante S, Iacopetta D, Cappello AR, Dolce 
V, Maggiolini M. G protein-coupled estrogen receptor 
mediates the up-regulation of fatty acid synthase induced 
by 17β-estradiol in cancer cells and cancer-associated 
fibroblasts. J Biol Chem. 2012; 287: 43234-43245. 
25. Vivacqua A, De Marco P, Santolla MF, Cirillo F, Pellegrino 
M, Panno ML, Abonante S, Maggiolini M. Estrogenic gper 
signalling regulates mir144 expression in cancer cells and 
cancer-associated fibroblasts (cafs). Oncotarget. 2015; 6: 
16573-16587. Doi: 10.18632/oncotarget.4117.
26. Lappano R, Pisano A, Maggiolini M. GPER Function in 
Breast Cancer: An Overview. Front Endocrinol (Lausanne). 
2014; 5:66. 
27. Santolla MF, Avino S, Pellegrino M, De Francesco EM, De 
Marco P, Lappano R, Vivacqua A, Cirillo F, Rigiracciolo 
DC, Scarpelli A, Abonante S, Maggiolini M. SIRT1 is 
involved in oncogenic signaling mediated by GPER in 
breast cancer. Cell Death and Disease. 2015; 6:e1834. 
Oncotarget109www.impactjournals.com/oncotarget
28. Santolla MF, De Francesco EM, Lappano R, Rosano C, 
Abonante S, Maggiolini M. Niacin activates the G protein 
estrogen receptor (GPER)-mediated signalling. Cell Signal. 
2014; 26: 1466-1475.
29. Lappano R, Rosano C, De Marco P, De Francesco EM, 
Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist 
in estrogen receptor-negative breast cancer cells. Mol Cell 
Endocrinol. 2010; 320: 162-170. 
30. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco 
EM, Abonante S, Rosano C, Maggiolini M. Bisphenol A 
induces gene expression changes and proliferative effects 
through GPER in breast cancer cells and cancer-associated 
fibroblasts. Environ Health Perspect. 2012; 120: 1177-1182.
31. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, 
Rosano C, Maggiolini M. MIBE acts as antagonist ligand of 
both estrogen receptor α and GPER in breast cancer cells. 
Breast Cancer Res. 2012; 14:R12.
32. Maggiolini M, Santolla MF, Avino S, Aiello F, 
Rosano C, Garofalo A, Grande F. Identification of two 
benzopyrroloxazines acting as selective GPER antagonists 
in breast cancer cells and cancer-associated fibroblasts. 
Future Med Chem. 2015; 7: 437-448. 
33. Sinicropi MS, Lappano R, Caruso A, Santolla MF, Pisano 
A, Rosano C, Capasso A, Panno A, Lancelot JC, Rault S, 
Saturnino C, Maggiolini M. (6-bromo-1,4-dimethyl-9H-
carbazol-3-yl-methylene)-hydrazine (carbhydraz) acts as a 
GPER agonist in breast cancer cells. Curr Top Med Chem. 
2015; 15: 1035-1042.
34. Lappano R, Rosano C, Pisano A, Santolla MF, De 
Francesco EM, De Marco P, Dolce V, Ponassi M, Felli 
L, Cafeo G, Kohnke FH, Abonante S, Maggiolini M. 
A calixpyrrole derivative acts as a GPER antagonist: 
mechanisms and models. Dis Model Mech. 2015; 8: 1237-
1246.
35. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz 
ER, Cappello AR, Dolce V, Abonante S, Pezzi V, 
Maggiolini M. Effects of Atrazine on Estrogen Receptor 
α- and G Protein-Coupled Receptor 30-Mediated Signalling 
and Proliferation in Cancer Cells and Cancer-Associated 
Fibroblasts. Environ Health Perspect. 2015; 123: 493-499.
36. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco 
EM, De Marco P, Ponassi M, Spallarossa A, Ranise A, 
Maggiolini M. Two novel GPER agonists induce gene 
expression changes and growth effects in cancer cells. Curr 
Cancer Drug Targets. 2012; 12: 531-542.
37. Funder JW. GPR30, mineralocorticoid receptors, and the 
rapid vascular effects of aldosterone. Hypertension. 2011; 
57: 370-372. 
38. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman 
RD. Aldosterone mediates its rapid effects in vascular 
endothelial cells through GPER activation. Am J Physiol 
Cell Physiol. 2013; 304: C532-540. 
39. Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz 
JE, Koch WJ, Brailoiu E. Aldosterone increases cardiac 
vagal tone via G protein-coupled oestrogen receptor 
activation. J Physiol. 2013; 591: 4223-4235. 
40. Ren Y, D’Ambrosio MA, Garvin JL, Leung P, Kutskill K, 
Wang H, Peterson EL, Carretero OA. Aldosterone sensitizes 
connecting tubule glomerular feedback via the aldosterone 
receptor GPR30. Am J Physiol Renal Physiol. 2014; 307: 
F427-434. 
41. Wendler A, Wehling M. Is GPR30 the membrane 
aldosterone receptor postulated 20 years ago? Hypertension. 
2011; 57:e16.
42. Barton M, Meyer MR. Nicolaus Copernicus and the rapid 
vascular responses to aldosterone. Trends Endocrinol 
Metab. 2015; 26: 396-398. 
43. Feldman RD, Limbird LE. Copernicus Revisited: 
Overturning Ptolemy’s View of the GPER Universe. Trends 
Endocrinol Metab. 2015; 26: 592-594. 
44. Cheng SB, Dong J, Pang Y, LaRocca J, Hixon M, Thomas 
P, Filardo EJ. Anatomical location and redistribution of G 
protein-coupled estrogen receptor-1 during the estrus cycle 
in mouse kidney and specific binding to estrogens but not 
aldosterone. Mol Cell Endocrinol. 2014; 382: 950-959. 
45. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. 
Aldosterone increases NHE-1 expression and induces 
NHE-1-dependent hypertrophy in neonatal rat ventricular 
myocytes. Hypertension. 2003; 42: 1171-1176. 
46. Bruder-Nascimento T, da Silva MA, Tostes RC. The 
involvement of aldosterone on vascular insulin resistance: 
implications in obesity and type 2 diabetes. Diabetol Metab 
Syndr. 2014; 6:90. 
47. Brown NJ. Contribution of aldosterone to cardiovascular 
and renal inflammation and fibrosis. Nat Rev Nephrol. 
2013; 9: 459-469.
48. Queisser N, Oteiza PI, Link S, Hey V, Stopper H, Schupp 
N. Aldosterone activates transcription factor Nrf2 in kidney 
cells both in vitro and in vivo. Antioxid Redox Signal. 
2014; 21: 2126-2142.
49. Grossmann C, Husse B, Mildenberger S, Schreier B, 
Schuman K, Gekle M. Colocalization of mineralocorticoid 
and EGF receptor at the plasma membrane. Biochim. 
Biophys. Acta. 2010; 1803: 584-590.
50. Jahn GA, Moguilewsky M, Houdebine LM, Djiane 
J. Binding and action of glucocorticoids and 
mineralocorticoids in rabbit mammary gland. Exclusive 
participation of glucocorticoid type II receptors for 
stimulation of casein synthesis. Mol Cell Endocrinol. 1987; 
52: 205-212.
51. Rabbitt EH, Gittoes NJ, Stewart PM, Hewison M. 11beta-
hydroxysteroid dehydrogenases, cell proliferation and 
malignancy. J Steroid Biochem Mol Biol. 2003; 85: 415-
421.
52. Sasano H, Frost AR, Saitoh R, Matsunaga G, Nagura 
H, Krozowski ZS, Silverberg SG. Localization of 
mineralocorticoid receptor and 11 beta-hydroxysteroid 
dehydrogenase type II in human breast and its disorders. 
Oncotarget110www.impactjournals.com/oncotarget
Anticancer Res. 1997; 17: 2001-2007.
53. Kim CH, Cho YS. Selection and optimization of MCF-
7 cell line for screening selective inhibitors of 11beta-
hydroxysteroid dehydrogenase 2. Cell Biochem Funct. 
2010; 28: 440-447.
54. De Francesco EM, Angelone T, Pasqua T, Pupo M, Cerra 
MC, Maggiolini M. GPER mediates cardiotropic effects in 
spontaneously hypertensive rat hearts. PLoS One. 2013; 8: 
e69322. 
55. Filice E, Angelone T, De Francesco EM, Pellegrino D, 
Maggiolini M, Cerra MC. Crucial role of phospholamban 
phosphorylation and S-nitrosylation in the negative 
lusitropism induced by 17β-estradiol in the male rat heart. 
Cell Physiol Biochem. 2011; 28: 41-52. 
56. Lappano R, Maggiolini M. G protein-coupled receptors: 
novel targets for drug discovery in cancer. Nat Rev Drug 
Discov. 2011; 10: 47-60. 
57. Lappano R, Maggiolini M. GPCRs and cancer. Acta 
Pharmacol Sin. 2012; 33: 351-362. 
58. Vivacqua A, Romeo E, De Marco P, De Francesco 
EM, Abonante S, Maggiolini M. GPER mediates 
the Egr-1 expression induced by 17β-estradiol and 
4-hydroxitamoxifen in breast and endometrial cancer cells. 
Breast Cancer Res Treat. 2012; 133: 1025-1035. 
59. Lappano R, De Marco P, De Francesco EM, Chimento A, 
Pezzi V, Maggiolini M. Cross-talk between GPER and 
growth factor signalling. J Steroid Biochem Mol Biol. 2013; 
137: 50-56. 
60. De Marco P, Cirillo F, Vivacqua A, Malaguarnera R, 
Belfiore A, Maggiolini M. Novel Aspects Concerning the 
Functional Cross-Talk between the Insulin/IGF-I System 
and Estrogen Signalling in Cancer Cells. Front Endocrinol 
(Lausanne). 2015; 6:30. 
61. Bartella V, De Marco P, Malaguarnera R, Belfiore A, 
Maggiolini M. New advances on the functional cross-talk 
between insulin-like growth factor-I and estrogen signalling 
in cancer. Cell Signal. 2012; 24: 1515-1521. 
62. Madeo A, Maggiolini M. Nuclear alternate estrogen 
receptor GPR30 mediates 17beta-estradiol-induced gene 
expression and migration in breast cancer-associated 
fibroblasts. Cancer Res. 2010; 70: 6036-6046. 
63. Pupo M, Pisano A, Abonante S, Maggiolini M, Musti AM. 
GPER activates Notch signalling in breast cancer cells and 
cancer-associated fibroblasts (CAFs). Int J Biochem Cell 
Biol. 2014; 46: 56-67. 
64. Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, 
Abonante S, Gasperi-Campani A, Pezzi V, Maggiolini M. 
The nuclear localization signal is required for nuclear GPER 
translocation and function in breast Cancer-Associated 
Fibroblasts (CAFs). Mol Cell Endocrinol. 2013; 376: 23-32. 
65. McEneaney V, Harvey BJ, Thomas W. Aldosterone rapidly 
activates protein kinase D via a mineralocorticoid receptor/
EGFR trans-activation pathway in the M1 kidney CCD cell 
line. J Steroid Biochem Mol Biol. 2007; 107: 180-190.
66. De Giusti VC, Nolly MB, Yeves AM, Caldiz CI, Villa-
Abrille MC, Chiappe de Cingolani GE, Ennis IL, Cingolani 
HE, Aiello EA. Aldosterone stimulates the cardiac 
Na(+)/H(+) exchanger via transactivation of the epidermal 
growth factor receptor. Hypertension. 2011; 58: 912-919.
67. Morgado-Pascual JL, Rayego-Mateos S, Valdivielso JM, 
Ortiz A, Egido J, Ruiz-Ortega M. Paricalcitol Inhibits 
Aldosterone-Induced Proinflammatory Factors by 
Modulating Epidermal Growth Factor Receptor Pathway in 
Cultured Tubular Epithelial Cells. Biomed Res Int. 2015; 
2015:783538. 
68. Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia 
and acidosis in carcinogenesis and tumor progression. 
Semin Cancer Biol. 2008; 18: 330-337. 
69. Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor 
microenvironment and metabolic synergy in breast cancers: 
critical importance of mitochondrial fuels and function. 
Semin Oncol. 2014; 41: 195-216. 
70. De Francesco EM, Lappano R, Santolla MF, Marsico 
S, Caruso A, Maggiolini M. HIF-1α/GPER signalling 
mediates the expression of VEGF induced by hypoxia in 
breast cancer associated fibroblasts (CAFs). Breast Cancer 
Res. 2013; 15:R64.
71. De Francesco EM, Pellegrino M, Santolla MF, Lappano 
R, Ricchio E, Abonante S, Maggiolini M. GPER mediates 
activation of HIF1α/VEGF signalling by estrogens. Cancer 
Res. 2014; 74: 4053-4064. 
72. Recchia AG, De Francesco EM, Vivacqua A, Sisci 
D, Panno ML, Andò S, Maggiolini M. The G protein-
coupled receptor 30 is up-regulated by hypoxia-inducible 
factor-1alpha (HIF-1alpha) in breast cancer cells and 
cardiomyocytes. J Biol Chem. 2011; 286: 10773-10782. 
73. Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, 
Santolla MF, De Marco P, Cirillo F, Cappello AR, Dolce 
V, Belfiore A, Maggiolini M, De Francesco EM. Copper 
activates HIF-1α/GPER/VEGF signalling in cancer 
cells. Oncotarget. 2015; 6:34158-77. doi: 10.18632/
oncotarget.5779.
74. Barton M, Prossnitz ER. Emerging roles of GPER in 
diabetes and atherosclerosis. Trends Endocrinol Metab. 
2015; 26: 185-192. 
75. Feldman RD, Gros R. scular effects of aldosterone: sorting 
out the receptors and the ligands. Clin Exp Pharmacol 
Physiol. 2013; 40: 916-921.
76. Brossa A, Grange C, Mancuso L, Annaratone L, Satolli 
MA, Mazzone M, Camussi G, Bussolati B. Sunitinib but 
not VEGF blockade inhibits cancer stem cell endothelial 
differentiation. Oncotarget. 2015; 6: 11295-11309. doi: 
10.18632/oncotarget.3123.
77. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, 
Camussi G. Isolation and characterization of human breast 
tumor-derived endothelial cells. Oncol Rep. 2006; 15: 381-
386.
78. Fiorio Pla A, Ong HL, Cheng KT, Brossa A, Bussolati B, 
Oncotarget111www.impactjournals.com/oncotarget
Lockwich T, Paria B, Munaron L, Ambudkar IS. TRPV4 
mediates tumor-derived endothelial cell migration via 
arachidonic acid-activated actin remodeling. Oncogene. 
2012; 31: 200-212.
79. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, 
Madeo A, Lappano R, Pandey DP, Picard D, Mauro L, 
Andò S, Maggiolini M. Epidermal growth factor induces G 
protein-coupled receptor 30 expression in estrogen receptor-
negative breast cancer. Endocrinology. 2008; 149: 3799-
3808.
80. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla 
MF, Morcavallo A, Pezzi V, Belfiore A, Maggiolini M. 
Insulin-like growth factor-I regulates GPER expression and 
function in cancer cells. Oncogene. 2013; 32: 678-688. 
81. De Marco P, Romeo E, Vivacqua A, Malaguarnera R, 
Abonante S, Romeo F, Pezzi V, Belfiore A, Maggiolini M. 
GPER1 is regulated by insulin in cancer cells and cancer-
associated fibroblasts. Endocr Relat Cancer. 2014; 21: 739-
753. 
